All In Biotech

Drug Trial Radar · NCT01125748

A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy

A Phase IV, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-term Therapy (XPORT)

Last checked: Nov 20, 2026Latest source record: Oct 15, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

May 2010

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
May 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 17 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, double-blind, placebo-controlled, 2-arm, 1-year study of participants who completed the EXCELS study (NCT00252135) and had received long-term treatment with Xolair. In addition, participants who did not participate in the EXCELS study but received long-term (\~5 years) treatment with Xolair were allowed to enter the study.

Conditions

  • Allergic Asthma

Interventions

  • OmalizumabDrug

    Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.

  • PlaceboDrug

    Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.

  • Asthma therapiesDrug

    Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Not Experiencing a Protocol-defined Severe Exacerbation During the StudyTime frame: Baseline to the end of the study (up to 52 weeks)

Locations

100 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Huntsville, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Bakersfield, California

  • Site not named

    Fresno, California

  • Site not named

    Fresno, California

  • Site not named

    Granada Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Napa, California

  • Site not named

    Redwood City, California

  • Site not named

    Sacramento, California

  • Site not named

    San Francisco, California

  • Site not named

    San Mateo, California

  • Site not named

    Studio City, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Centennial, Colorado

  • Site not named

    Thornton, Colorado

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Bay Pines, Florida

  • Site not named

    Clearwater, Florida

  • Site not named

    Loxahatchee Groves, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Albany, Georgia

  • Site not named

    Columbus, Georgia

  • Site not named

    Gainesville, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Glen Carbon, Illinois

  • Site not named

    Park Ridge, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Overland Park, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Lexington, Kentucky

  • Site not named

    Mandeville, Louisiana

  • Site not named

    Metairie, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Ellicott City, Maryland

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.